Anticoagulation Management for Atherosclerotic Embolism

Initiation and Discontinuation of Anticoagulation

The American Geriatrics Society recommends that heparin infusion should be discontinued after the INR has been therapeutic (≥2.0) for at least 24 hours with a minimum overlap of 2 consecutive measurements taken more than 24 hours apart, typically achieved within 5-7 days of initiating warfarin therapy 1
The American Geriatrics Society suggests starting warfarin therapy on day 1 or day 2 of heparin initiation rather than waiting, as early overlap shortens total heparin duration and reduces complications 1
The American Geriatrics Society recommends avoiding loading doses of warfarin in older adults with atherosclerotic disease—use maintenance dosing (typically <5 mg daily) due to increased pharmacodynamic sensitivity 1
Heparin may be discontinued when the INR has been in therapeutic range (2.0-3.0) for at least 2 measurements, taken more than 24 hours apart, and a minimum of 5 days of warfarin therapy has been completed, with a target INR of 2.5 (range 2.0-3.0) 1, 2

The American College of Chest Physicians recommends considering extended anticoagulation beyond 3 months if bleeding risk is low-to-moderate, with annual reassessment, for patients with atherosclerotic embolism, which represents an unprovoked thrombotic event with a persistent risk factor (ongoing atherosclerotic disease) 3, 5
The American College of Chest Physicians suggests that patients with low bleeding risk (age <70 years, no prior major bleeding, no concomitant antiplatelet therapy, and good medication adherence) should be recommended for extended therapy (Grade 1B) 3, 4
The American College of Chest Physicians recommends that patients with high bleeding risk (age ≥80 years, previous major bleeding, recurrent falls, or severe renal or hepatic impairment) should stop anticoagulation at 3 months (Grade 1B) 3, 5

The American Geriatrics Society recommends checking INR daily until stable and therapeutic, then 2-3 times weekly for 1-2 weeks, then weekly for 1 month, and then monthly thereafter if stable 1
The American Geriatrics Society suggests monitoring more frequently in older adults due to increased INR fluctuations with illness or medication changes, and reassessing annually if extended anticoagulation is chosen, evaluating bleeding risk, medication adherence, and patient preferences 1, 3, 5